Teachers Retirement System of The State of Kentucky Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

view original post

Teachers Retirement System of The State of Kentucky lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 1.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,921 shares of the biopharmaceutical company’s stock after selling 333 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Regeneron Pharmaceuticals were worth $14,612,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its position in shares of Regeneron Pharmaceuticals by 2.6% during the 4th quarter. BlackRock Inc. now owns 9,610,871 shares of the biopharmaceutical company’s stock valued at $6,069,457,000 after acquiring an additional 244,009 shares during the period. Vanguard Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 8,360,330 shares of the biopharmaceutical company’s stock valued at $5,839,023,000 after acquiring an additional 201,815 shares during the period. Capital World Investors lifted its position in shares of Regeneron Pharmaceuticals by 11.8% during the 1st quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company’s stock valued at $4,155,451,000 after acquiring an additional 626,199 shares during the period. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 6.8% during the 1st quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company’s stock valued at $3,579,729,000 after acquiring an additional 325,645 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 1,977,302 shares of the biopharmaceutical company’s stock valued at $1,245,725,000 after acquiring an additional 237,090 shares during the period. 84.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 10,453 shares of the company’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $621.29, for a total transaction of $6,494,344.37. Following the completion of the sale, the director now directly owns 18,408 shares of the company’s stock, valued at approximately $11,436,706.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of the business’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $581.53, for a total value of $639,683.00. Following the transaction, the executive vice president now owns 19,644 shares in the company, valued at approximately $11,423,575.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 10,453 shares of the business’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $621.29, for a total transaction of $6,494,344.37. Following the completion of the transaction, the director now owns 18,408 shares in the company, valued at approximately $11,436,706.32. The disclosure for this sale can be found here. In the last three months, insiders sold 56,740 shares of company stock valued at $35,478,694. Company insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6 %

Shares of Regeneron Pharmaceuticals stock opened at $710.30 on Friday. The company has a fifty day moving average price of $616.00 and a 200 day moving average price of $638.45. The company has a current ratio of 5.12, a quick ratio of 4.39 and a debt-to-equity ratio of 0.13. Regeneron Pharmaceuticals, Inc. has a twelve month low of $538.01 and a twelve month high of $754.67. The stock has a market cap of $77.43 billion, a price-to-earnings ratio of 14.18, a price-to-earnings-growth ratio of 2.41 and a beta of 0.29.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing analysts’ consensus estimates of $9.94 by ($0.17). Regeneron Pharmaceuticals had a return on equity of 36.17% and a net margin of 39.97%. The business had revenue of $2.86 billion for the quarter, compared to analysts’ expectations of $2.80 billion. During the same period last year, the company posted $27.97 earnings per share. The firm’s revenue for the quarter was down 44.4% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. SVB Leerink lifted their price objective on Regeneron Pharmaceuticals from $630.00 to $756.00 and gave the stock a “market perform” rating in a research report on Friday, September 9th. Piper Sandler lifted their price objective on Regeneron Pharmaceuticals from $692.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday. Canaccord Genuity Group lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock a “buy” rating in a research report on Friday. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $740.00 to $925.00 in a research report on Monday, September 12th. Finally, Cowen lifted their price objective on Regeneron Pharmaceuticals to $655.00 in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $746.33.

Regeneron Pharmaceuticals Company Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Receive News & Ratings for Regeneron Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts